drugset / Trial / NCT06856278
Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC
NaSingle-groupOpen-labelTreatment
Summary
The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.
Timeline
- Start
- 2025-02-22
- Primary completion
- 2028-12-31
- Completion
- 2029-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NKG2D CAR-NK | Cell therapy | — | — |